Objectives: We examined our experience with inferior vena cava filters to assess whether we conformed to the American College of Chest Physicians (ACCP) and the Society of Interventional Radiology (SIR) guidelines and to evaluate the reasons for any discrepancy.
Methods: This was a retrospective medical record review of patients having inferior vena cava filters placed in two New York City hospitals during a 34-month period. The indications for filter placement, the type of filter used, and the conformity with the two guidelines were noted.
Results: A total of 345 filters were placed; 41.4% were permanent and 58.6% were optional. Compliance with SIR guidelines was 95.7% and 41.3% with ACCP guidelines. A total of 173 patients (50.4%) did not conform to the ACCP guidelines while meeting the SIR guidelines. Seventy-one of these patients had a documented venous thromboembolism in the perioperative period, 24 experienced recurrent or progressive venous thromboembolism while on anticoagulation, and 24 were judged to have advanced cardiopulmonary disease. Thirty patients had prophylactic filters, the majority of whom were in the perioperative period. These conditions were the main causes of discrepancy between the guidelines.
Conclusions: Compliance with the ACCP guidelines is poor in this series; however, much of the discrepancy is based on grade 2C evidence. Only grade 1 evidence will reconcile the differences between the two guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14423/SMJ.0000000000000164 | DOI Listing |
Support Care Cancer
January 2025
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Background: Remote monitoring using electronic patient-reported outcomes (ePROs) may help identify immune-related adverse events (irAEs) and direct self-management. There is no consensus regarding thresholds to alert providers about potentially severe irAEs or when to instigate evidence-based self-management. We aimed to develop consensus around alert thresholds and self-management advice for side-effects suggestive of an irAE which can be deployed as part of remote monitoring systems.
View Article and Find Full Text PDFSupport Care Cancer
January 2025
Department of Health Services Research, Peter MacCallum Cancer Centre, Victoria, Australia.
Purpose: To evaluate cancer patients' willingness to pay for exercise services and oncology health professionals' perception of patients' willingness to pay.
Methods: A mixed-methods design was used. Online questionnaires and semi-structured interviews were administered to people with any type of cancer and oncology health professionals delivering clinical care.
Front Immunol
January 2025
Yi-Huan Genitourinary Cancer Group, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Primary small cell neuroendocrine carcinoma of the prostate is extremely rare, highly aggressive, and has a very poor prognosis, with an overall survival typically not exceeding one year. Standard treatment is generally based on the regimen for small cell lung cancer (SCLC), with guidelines recommending etoposide combined with cisplatin (EP regimen) as the first-line treatment. However, their therapeutic effects are limited.
View Article and Find Full Text PDFBJU Int
January 2025
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).
Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.
EBioMedicine
January 2025
Imperial College London, Department of Infectious Disease, UK. Electronic address:
Background: We report findings from an experimental medicine study of rationally designed prefusion stabilised native-like HIV envelope glycoprotein (Env) immunogens, representative of global circulating strains, delivered by sequential intramuscular injection.
Methods: Healthy adult volunteers were enrolled into one of five groups (A to E) each receiving a different schedule of one of two consensus Env immunogens (ConM SOSIP, ConS UFO, either unmodified or stabilised by chemical cross-linking, followed by a boost with two mosaic Env immunogens (Mos3.1 and Mos3.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!